Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Net income
Vera Therapeutics, Inc.'s net income for fiscal 2025 was −$299.6M, compared with −$152.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$401.9M. Over the past ten years it has ranged from −$299.6M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 4 consecutive fiscal years. Vera Therapeutics, Inc. ranks 573rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$299.6M | — |
| FY2024 | −$152.1M | — |
| FY2023 | −$96.0M | — |
| FY2022 | −$89.1M | — |
| FY2021 | −$32.6M | — |
| FY2020 | −$53.4M | — |
| FY2019 | −$11.9M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$109.5M | — |
| Mar 2026 | −$121.0M | — |
| Dec 2025 | −$91.1M | — |
| Sep 2025 | −$80.3M | — |
| 23 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| VERA Vera Therapeutics, Inc. | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item